Zometa & Osteonecrosis of the Jaw

Site Map

This Website is © Lorenzo de Magnifico - 2003-2005

Home Carcinoid Cancer My Noid Humor Carcinoid-Month Miscellaneous About Me Support

 

Zometa & Osteonecrosis of the Jaw

 

I have been getting Zometa infusions for my bone metastases since the fall of 2002.

In the summer of 2004, I began having a series of bad teeth problems; most of which can probably be explained by the following May 5, 2005, FDA release ...

 

Zometa (zoledronic acid)
Aredia (pamidronate disodium)

  • Audience: Dental and oncologic healthcare professionals
    Novartis and FDA notified dental healthcare professionals of revisions to the prescribing information to describe the occurrence of osteonecrosis of the jaw (ONJ) observed in cancer patients receiving treatment with intravenous bisphosphonates, Aredia (pamidronate disodium) and Zometa (zoledronic acid). The prescribing information recommends that cancer patients receive a dental examination prior to initiating therapy with intravenous bisphosphonates (Aredia and Zometa), and avoid invasive dental procedures while receiving bisphosphonate treatment. For patients who develop ONJ while on bisphosphonate therapy, dental surgery may exacerbate the condition.
  • Aredia is used in the treatment of hypercalcemia of malignancy, Pagetís disease, osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. Zometa is used in the treatment of hypercalcemia of malignancy, the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.

 

 

 

Click on the above image to see the entire release (in pdf format)

 

Larry

 

 

 

This page was last updated June 25 2005

Home Carcinoid Cancer My Noid Humor Carcinoid-Month Miscellaneous About Me Support